Breaking News Instant updates and real-time market news.

AAPL

Apple

$143.78

-14.165 (-8.97%)

, GWR

Genesee & Wyoming

$72.35

-1.46 (-1.98%)

10:16
01/03/19
01/03
10:16
01/03/19
10:16

Fly Intel: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Hold from Buy at Jefferies and Loop Capital, as well as to Neutral from Outperform at Macquarie. 2. Genesee & Wyoming (GWR) downgraded to Equal Weight from Overweight at Stephens with analyst Justin Long citing his view that a re-expansion in valuation multiples could be more challenging in the near-term given North American volume headwinds in the short line network, unknowns around the PSR impact and more concerning international macro data points. 3. Lumber Liquidators (LL) downgraded to Hold from Buy at Loop Capital with analyst Laura Champine saying she reduced her margin forecast to reflect a promotional environment. 4. American Electric (AEP) downgraded to Neutral from Buy at Mizuho with analyst Paul Fremont citing valuation. 5. AbbVie (ABBV) downgraded to Neutral from Buy at BofA/Merrill with analyst Jason Gerberry saying he sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

AAPL

Apple

$143.78

-14.165 (-8.97%)

GWR

Genesee & Wyoming

$72.35

-1.46 (-1.98%)

LL

Lumber Liquidators

$9.28

-0.7 (-7.01%)

AEP

American Electric

$73.14

0.19 (0.26%)

ABBV

AbbVie

$87.58

-1.64 (-1.84%)

  • 25

    Jan

  • 28

    Jan

  • 18

    May

AAPL Apple
$143.78

-14.165 (-8.97%)

01/03/19
01/03/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) upgraded to Neutral from Reduce at New Street with analyst Pierre Ferragu saying the news is as bad as can be and the thesis is "fully played out." 2. Alphabet (GOOG, GOOGL) upgraded to Buy from Hold at Canaccord with analyst Michael Graham saying revenue growth should continue in the 15-20% range for 2-3 years which coupled with abating margin pressure and share buybacks, should lead to over 15% earnings growth between 2020-2022. 3. First Solar (FSLR) upgraded to Buy from Neutral at Goldman Sachs with analyst Brian Lee saying solar stocks underperformed in 2018 as tariffs, China policy and oversupply drove a cyclical correction. 4. Stryker (SYK) upgraded to Outperform at Evercore ISI with analyst Ross Muken saying 2019 guidance has been de-risked following management commentary and said recent macro survey work suggests 7% organic growth is achievable. 5. Waters (WAT) upgraded to Neutral from Underperform at BofA/Merrill with analyst Derik de Bruin citing an aggressive share buyback program that offers earnings support. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/03/19
RILY
01/03/19
NO CHANGE
Target $62
RILY
Buy
B. Riley FBR an 'aggressive' buyer of Lumentum on today's selloff
B. Riley FBR analyst Dave Kang says he's an "aggressive" buyer today of Lumentum Holdings (LITE) on the selloff related to Apple's guidance cut last night. Apple weakness believe was already reflected in Lumentum's November preannouncement, Kang tells investors in a research note. He keeps a Buy rating on the shares with a $62 price target. The stock in early trading is down 8%, or $3.36, to $39.23.
01/03/19
MSCO
01/03/19
NO CHANGE
MSCO
Skyworks, Qorvo among semi names with most Apple exposure, says Morgan Stanley
Morgan Stanley analyst Craig Hettenbach maintains his Cautious view on the Semiconductors sector, telling investors that the sizeable iPhone miss in China and a weaker China PMI reading this week provide further evidence of a strong downward bias in "the most important growth region for semis." He sees more reasons for investors to reduce exposure to semis, rather than add, ahead of what he expects to be a challenging earnings season, Hettenbach noted. In terms of exposure to Apple (AAPL), he estimates Skyworks (SWKS) has 45% exposure, followed by Qorvo (QRVO) at about 35% and Broadcom (AVGO) at 15%- 20%. Beyond the companies with the greatest Apple exposure, Hettenbach also highlight risks to broad-based suppliers such as Texas Instruments (TXN), Amphenol (APH), ON Semiconductor (ON), NXP Semiconductors (NXPI), Analog Devices (ADI) and Cypress Semiconductor (CY), calling out ON as his top Underweight idea.
01/03/19
DADA
01/03/19
NO CHANGE
Target $260
DADA
Buy
Apple price target lowered to $260 from $280 at DA Davidson
DA Davidson analyst Tom Forte lowered his price target on Apple to $260 after its "rare" pre-announcement that highlighted the company's "tightrope" in traversing its China exposure with 20% of sales from the country amid the "prolonged and escalating" trade war. The analyst notes that while the iPhone sales for December quarter look to be disappointing, he was encouraged by the performance of other products and services in the quarter, keeping his Buy rating on the shares. Forte also believes that Apple may boost its stock buyback since it typically updates its capital program in April/May, given its $130B net cash balance and repeated intention to become net-cash neutral in the future.
GWR Genesee & Wyoming
$72.35

-1.46 (-1.98%)

11/02/18
FBCO
11/02/18
DOWNGRADE
Target $71
FBCO
Underperform
Genesee & Wyoming downgraded to Underperform from Outperform at Credit Suisse
Credit Suisse analyst Allison Landry downgraded Genesee & Wyoming two notches to Underperform from Outperform and cut her price target for shares to $71 from $90. In a research note to investors, Landry says her rationale is based on potentially meaningful short- to mid-term operating disruptions related to the Class I rollout of Precision Scheduled Railroading, operating leverage that is likely to be hampered by slowing volumes in North America, "chronic" underperformance in its U.K. franchise, a lack of M&A catalysts and a premium valuation that she feels is now unwarranted. She recommends investors consider taking profits given that she no longer has confidence in the company's earnings and cash flow trajectory.
11/02/18
FBCO
11/02/18
DOWNGRADE
FBCO
Underperform
Genesee & Wyoming downgraded to Underperform from Outperform at Credit Suisse
10/31/18
SBSH
10/31/18
DOWNGRADE
Target $90
SBSH
Neutral
Genesee & Wyoming downgraded to Neutral with $90 target at Citi
Citi analyst Christian Wetherbee last night downgraded Genesee & Wyoming to Neutral from Buy and lowered his price target for the shares to $90 from $95. The analyst says that while North America results were strong in Q3 and comps remain "reasonably favorable," he's getting "a bit more cautious" on the potential volume growth for 2019 given the maturing cycle and potential for tariff impacts to begin to be felt more clearly. As such, he expects "less help from multiple expansion in the current environment."
01/03/19
SPHN
01/03/19
DOWNGRADE
Target $83
SPHN
Equal Weight
Genesee & Wyoming downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Justin Long downgraded Genesee & Wyoming to Equal Weight from Overweight, citing his view that a re-expansion in valuation multiples could be more challenging in the near-term given North American volume headwinds in the short line network, unknowns around the PSR impact and more concerning international macro data points. Long lowered his price target on G&W shares to $83 from $95.
LL Lumber Liquidators
$9.28

-0.7 (-7.01%)

10/31/18
WEDB
10/31/18
NO CHANGE
Target $12
WEDB
Neutral
Lumber Liquidators price target lowered to $12 from $22 at Wedbush
Wedbush analyst Seth Basham lowered his price target for Lumber Liquidators to $12 from $22 after its Q3 results missed on the top line but beat on the bottom line. While Lumber Liquidators continues to refine its marketing strategy to boost traffic, including plans to enhance the customer experience through digital channels, the company has yet to find the correct balance between advertising, promotion and sales. He views its sales challenges as mostly self-inflicted and company-specific in nature, but Lumber Liquidators is also facing a slowing housing environment, heightened competition, and material Chinese tariff headwinds. Basham reiterates a Neutral rating on the shares.
11/01/18
RHCO
11/01/18
NO CHANGE
Target $13
RHCO
Hold
Lumber Liquidators price target lowered to $13 from $21 at SunTrust
SunTrust analyst Keith Hughes lowered his price target on Lumber Liquidators to $13 and kept his Hold rating, saying that while its Q3 profits topped expectations, the margin outlook was hampered by the "headwinds from upcoming tariffs, cost inflation, and a competitive environment that makes price realization very difficult". The analyst also notes slowing comps and weak traffic during Q3, even as he acknowledges that some of that slowdown comes from Lumber Liquidators moving away from its historical promotional approach.
01/03/19
LOOP
01/03/19
DOWNGRADE
Target $10
LOOP
Hold
Lumber Liquidators downgraded to Hold from Buy at Loop Capital
Loop Capital analyst Laura Champine downgraded Lumber Liquidators to Hold and cut her price target for the shares to $10 from $24. The analyst reduced her margin forecast to reflect a promotional environment. In 2019, lower sales and margins are likely as big-ticket home-related spending growth begins to fade, Champine tells investors in a research note. The analyst's 35c earnings per share estimate for Lumber Liquidators's 2019 is 20c lower than the consensus. However, she believes the stock's "trough valuation" should limit further downside.
10/30/18
LOOP
10/30/18
NO CHANGE
Target $24
LOOP
Buy
Lumber Liquidators trades at 'trough' valuation levels, says Loop Capital
Loop Capital analyst Laura Champine reiterates a Buy rating on Lumber Liquidators while reducing her price target for the shares to $24 from $25 following this morning's Q3 results. The analyst points out that the company's 2.1% same-store-sales in the quarter missed her 5% estimate. However, she notes that management in this morning's filing called out less promotional activity this Q3 versus last year. The stock, trading at 0.3 times 2019 estimated sales, presents a "trough valuation for a turnaround story that is returning to profitability in its second year of comp growth," Champine tells investors in a research note. She notes Lumber Liquidators' sales multiple is the lowest in her current coverage.
AEP American Electric
$73.14

0.19 (0.26%)

01/03/19
MZHO
01/03/19
DOWNGRADE
Target $70
MZHO
Neutral
American Electric downgraded to Neutral on valuation at Mizuho
Mizuho analyst Paul Fremont downgraded American Electric Power to Neutral from Buy and lowered his price target for the shares to $70 from $76. The analyst cites valuation for the downgrade as he believes the company should not be given a premium multiple. Over the past year, American Electric shares have outperformed an index of peers by roughly 6%, Fremont tells investors in a research note.
01/03/19
MZHO
01/03/19
DOWNGRADE
MZHO
Neutral
American Electric downgraded to Neutral from Buy at Mizuho
09/10/18
GUGG
09/10/18
UPGRADE
Target $77
GUGG
Buy
American Electric upgraded to Buy on valuation, catalysts at Guggenheim
As previously reported, Guggenheim upgraded American Electric to Buy from Neutral and raised its price target to $77 from $64. Analyst Shahriar Pourreza believes shares trade at an attractive valuation with catalysts ahead following the removal of the overhang from Wind Catcher. Pourreza sees a multiple re-rating on shares from incremental capital to be added to the plan in the form of gas infrastructure, renewables, and grid modernization, which could lead to higher earnings, and potential monetization of underperforming assets and redeploy proceeds into other jurisdictions with higher returns.
09/21/18
09/21/18
NO CHANGE

Morgan Stanley shakes up utility ratings, upgrades Atmos, downgrades Xcel
As previously reported, Morgan Stanley analyst Stephen Byrd upgraded Atmos Energy (ATO) to Overweight from Equal Weight as he laid out his favorite ideas in regulated utilities based on his estimates of their 2020 earnings power. Byrd believes Atmos' 5% discount to the gas utility group undervalues its "best-in-class" growth outlook and attractive regulatory environment, he tells investors. Byrd also downgraded Xcel Energy (XEL) to Equal Weight from Overweight, telling investors that he sees modest level of upside remaining in the stock and few near-term catalysts for outperformance. In shifting his focus to 2020 earnings power, Byrd also identifies FirstEnergy (FE), PSEG (PEG), American Electric (AEP) and NextEra Energy (NEE) as stocks in the group with undervalued growth.
ABBV AbbVie
$87.58

-1.64 (-1.84%)

01/03/19
BOFA
01/03/19
DOWNGRADE
Target $95
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill
As noted earlier, BofA/Merrill analyst Jason Gerberry downgraded AbbVie to Neutral from Buy and lowered his price target to $95 from $98 as part of his broader research note on the Phamaceuticals sector partially titled "Preference for value, defensive + pipeline optionality". The analyst sees "limited upside to shares" relative to his price objective and also cites a more "unfavorable macro backdrop for companies with high single product concentration risk". Gerber believes that AbbVie would have to "meaningfully beat consensus forecasts on key new product launches" to reduce investor concerns over the loss of exclusivity for Humira and Imbruvica.
12/13/18
12/13/18
UPGRADE

Outperform
Galapagos NV upgraded to Outperform at Credit Suisse after removal of headwinds
As previously reported, Credit Suisse analyst Vamil Divan upgraded Galapagos NV (GLPG) to Outperform from Neutral following removal of headwinds and given the multiple assets that the company now has in mid-late stage development. Among the headwinds were the cystic fibrosis franchise, which he had concern about and is being run by AbbVie (ABBV), and clarity on the U.S. filing timelines for lead asset filgotinib, the analyst notes. Divan also raised his price target on Galapagos NV shares to EUR130 from EUR90.
12/26/18
STPT
12/26/18
INITIATION
STPT
Buy
AbbVie initiated with a Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas initiated AbbVie with a Buy rating.
01/03/19
BOFA
01/03/19
DOWNGRADE
BOFA
Neutral
AbbVie downgraded to Neutral from Buy at BofA/Merrill

TODAY'S FREE FLY STORIES

HPQ

HP Inc.

$20.17

0.05 (0.25%)

, XRX

Xerox

$38.95

0.295 (0.76%)

20:56
11/17/19
11/17
20:56
11/17/19
20:56
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

HPQ

HP Inc.

$20.17

0.05 (0.25%)

XRX

Xerox

$38.95

0.295 (0.76%)

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

PCG

PG&E

$7.41

0.71 (10.60%)

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

SNE

Sony

$62.03

0.23 (0.37%)

BR

Broadridge

$119.80

0.485 (0.41%)

MDT

Medtronic

$112.11

2.9 (2.66%)

DIS

Disney

$144.63

-2.56 (-1.74%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 26

    Nov

  • 09

    Dec

  • 07

    Jan

RCEL

Avita Medical

$8.13

-0.06 (-0.73%)

20:39
11/17/19
11/17
20:39
11/17/19
20:39
Hot Stocks
Avita Medical appoints David McIntyre CFO »

AVITA Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

20:37
11/17/19
11/17
20:37
11/17/19
20:37
Recommendations
Eidos Therapeutics analyst commentary at Piper Jaffray »

Piper Jaffray sees Eidos…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

COO

Cooper Companies

$301.97

2.64 (0.88%)

20:30
11/17/19
11/17
20:30
11/17/19
20:30
Recommendations
Cooper Companies analyst commentary at Piper Jaffray »

Piper Jaffray reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CRM

Salesforce

$163.20

0.18 (0.11%)

20:21
11/17/19
11/17
20:21
11/17/19
20:21
Recommendations
Salesforce analyst commentary at Jefferies »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

  • 16

    Dec

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Breaking Earnings news story on Cabot Microelectronics »

Cabot Microelectronics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:15
11/17/19
11/17
20:15
11/17/19
20:15
Earnings
Cabot Microelectronics sees Q1 total revenue approximately flat »

For Q1, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

CCMP

Cabot Microelectronics

$155.89

2.68 (1.75%)

20:14
11/17/19
11/17
20:14
11/17/19
20:14
Earnings
Cabot Microelectronics reports Q4 EPS $1.68, consensus $1.63 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

JEF

Jefferies Financial Group

$19.08

0.16 (0.85%)

20:13
11/17/19
11/17
20:13
11/17/19
20:13
Hot Stocks
Jefferies Financial Group to sell 31% interest in National Beef to Marfrig »

Jefferies Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NIO

NIO Inc.

$1.82

0.07 (4.01%)

20:11
11/17/19
11/17
20:11
11/17/19
20:11
Hot Stocks
NIO Inc. appoints Wei Feng CFO »

NIO Inc. announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

20:09
11/17/19
11/17
20:09
11/17/19
20:09
Hot Stocks
Barrick Gold to sell 50% stake in Australian mine for $750M in cash »

Barrick Gold Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOLD

Barrick Gold

$16.57

-0.095 (-0.57%)

15:40
11/17/19
11/17
15:40
11/17/19
15:40
Periodicals
Saracen close to buying Barrick Gold mine stake for $750M, Bloomberg says »

Saracen Mineral Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESPR

Esperion

$40.51

0.67 (1.68%)

15:11
11/17/19
11/17
15:11
11/17/19
15:11
Hot Stocks
Esperion presents pooled analyses from four Phase 3 bempedoic acid studies »

Esperion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

PCG

PG&E

$7.41

0.71 (10.60%)

15:06
11/17/19
11/17
15:06
11/17/19
15:06
Hot Stocks
PG&E monitoring potential weather event that could lead to power shutoffs »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

XRX

Xerox

$38.95

0.295 (0.76%)

, HPQ

HP Inc.

$20.17

0.05 (0.25%)

15:04
11/17/19
11/17
15:04
11/17/19
15:04
Hot Stocks
HP unanimously rejects unsolicited Xerox proposal »

HP Inc. (HPQ) announced…

XRX

Xerox

$38.95

0.295 (0.76%)

HPQ

HP Inc.

$20.17

0.05 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 09

    Dec

FOX

Fox Corp.

$33.60

0.14 (0.42%)

, FOXA

Fox Corp.

$34.26

0.04 (0.12%)

14:49
11/17/19
11/17
14:49
11/17/19
14:49
On The Fly
Box Office Battle: 'Ford v Ferrari' races to top, 'Charlie's Angels' disappoints »

"Box Office Battle" is…

FOX

Fox Corp.

$33.60

0.14 (0.42%)

FOXA

Fox Corp.

$34.26

0.04 (0.12%)

LGF.A

Lionsgate

$9.67

0.315 (3.37%)

LGF.B

Lionsgate

$9.07

0.345 (3.96%)

SNE

Sony

$62.03

0.23 (0.37%)

VIA

Viacom

$26.59

1.28 (5.06%)

VIAB

Viacom

$23.07

0.59 (2.62%)

T.CA

TELUS Corp. (Toronto)

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$144.63

-2.56 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

13:36
11/17/19
11/17
13:36
11/17/19
13:36
Periodicals
J&J rushed to test baby powder and got complicated results, WSJ says »

In October, Johnson &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 07

    Dec

  • 21

    Jan

BA

Boeing

$371.55

4.25 (1.16%)

13:24
11/17/19
11/17
13:24
11/17/19
13:24
Periodicals
Boeing 737 makes emergency landing after engine malfunction, NY Post says »

A Canada-bound flight…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:17
11/17/19
11/17
13:17
11/17/19
13:17
Hot Stocks
Data shows AstraZeneca's Brilinta reduces risks of clinically relevant bleeding »

New results from a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

LLY

Eli Lilly

$113.18

1.8 (1.62%)

13:11
11/17/19
11/17
13:11
11/17/19
13:11
Hot Stocks
Analysis shows Jardiance decreased risk of hospitalization for heart failure »

A new interim analysis of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

AZN

AstraZeneca

$47.46

0.09 (0.19%)

13:09
11/17/19
11/17
13:09
11/17/19
13:09
Hot Stocks
AstraZeneca says data shows Farxiga reduces risks in heart failure patients »

AstraZeneca announced new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 07

    Dec

BA

Boeing

$371.55

4.25 (1.16%)

13:05
11/17/19
11/17
13:05
11/17/19
13:05
Hot Stocks
Boeing, Biman announce order for two 787-9 Dreamliner jets »

Boeing and Biman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBIO

BridgeBio

$28.26

0.55 (1.98%)

, EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

13:03
11/17/19
11/17
13:03
11/17/19
13:03
Hot Stocks
BridgeBio, Eidos present 'positive' data from Phase 2 clinical trial of AG10 »

BridgeBio Pharma (BBIO)…

BBIO

BridgeBio

$28.26

0.55 (1.98%)

EIDX

Eidos Therapeutics

$46.58

1.33 (2.94%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

CLBS

Caladrius

$2.64

-0.06 (-2.22%)

13:01
11/17/19
11/17
13:01
11/17/19
13:01
Hot Stocks
Caladrius reports 'positive' results for CLBS16 from ESCaPE-CMD trial »

Caladrius Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNSA

Kiniksa

$6.52

0.1 (1.56%)

12:59
11/17/19
11/17
12:59
11/17/19
12:59
Hot Stocks
Kiniksa presents Rilonacept final Phase 2 clinical data »

Kiniksa Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 21

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.